Inflammation and prostate cancer: The role of interleukin 6 (IL-6)

BJU International

Volumn 113, Issue 6, 2014, Pages 986-992

  Nguyen, Daniel P ^b,c   Li, Jinyi ^a   Tewari, Ashutosh K ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

androgen receptor; inflammation; interleukin 6; metastasis; prostate cancer; tumour growth

Indexed keywords

ANDROGEN RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; STAT PROTEIN;

APOPTOSIS; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL HOMING; CELL PROLIFERATION; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR PROMOTION;

ANDROGEN RECEPTOR; INFLAMMATION; INTERLEUKIN-6; METASTASIS; PROSTATE CANCER; TUMOUR GROWTH;

HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84902168138     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12452     Document Type: Review

References (55)

1. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70
2. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674
3. Shacter E, Weitzman SA,. Chronic inflammation and cancer. Oncology 2002; 16: 217-226
4. Sfanos KS, De Marzo AM,. Prostate cancer and inflammation: the evidence. Histopathology 2012; 60: 199-215
5. Haverkamp J, Charbonneau B, Ratliff TL,. Prostate inflammation and its potential impact on prostate cancer: a current review. J Cell Biochem 2008; 103: 1344-1353
6. Gueron G, De Siervi A, Vazquez E,. Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis 2012; 15: 213-221
7. Neurath MF, Finotto S,. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 2011; 22: 83-89
8. Ammirante M, Luo J, Grivennikov S, Nedospasov S, Karin M,. B-cell derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010; 464: 302-305
9. Ebelt K, Babaryka G, Figel AM, et=al. Dominance of CD4 + lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate 2008; 68: 1-10
10. Sfanos KS, Bruno TC, Maris CH, et=al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008; 14: 3254-3261
11. Fujimoto M, Nakano M, Terabe F, et=al. The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J Immunol 2011; 186: 32-40
12. Wu CT, Hsieh CC, Lin CC, Chen WC, Hong JH, Chen MF,. Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells. J Mol Med 2012; 90: 1343-1355
13. Wong CP, Bray TM, Ho E,. Induction of proinflammatory response in prostate cancer epithelial cells by activated macrophages. Cancer Lett 2009; 276: 38-46
14. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F,. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374: 1-20
15. Rose-John S, Elson G, Jones SA,. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006; 80: 227-236
16. Qiu Y, Ravi L, Kung HJ,. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 1998; 393: 83-85
17. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC,. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999; 161: 182-187
18. Wise GJ, Marella VK, Talluri G, Shirazian D,. Cytokine variations in patients with hormone treated prostate cancer. J Urol 2000; 164: 722-725
19. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM,. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001; 58: 1008-1015
20. George DJ, Halabi S, Shepard TF, et=al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 2005; 11: 1815-1820
21. Okamoto M, Lee C, Oyasu R,. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997; 57: 141-146
22. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW,. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999; 38: 199-207
23. Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC,. Interleukin- 6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 2007; 67: 764-773
24. Steiner H, Godoy-Tundidor S, Rogatsch H, et=al. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol 2003; 162: 655-663
25. Smith PC, Keller ET,. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 2001; 48: 47-53
26. Cardillo MR, Ippoliti F,. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res 2006; 26: 3409-3416
27. Sivashanmugam P, Tang L, Daaka Y,. Interleukin 6 mediates the lysophosphatidic acid-regulated cross-talk between stromal and epithelial prostate cancer cells. J Biol Chem 2004; 279: 21154-21159
28. Giri D, Ozen M, Ittmann M,. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001; 159: 2159-2165
29. Rojas A, Liu G, Coleman I, et=al. IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-1R. Oncogene 2011; 30: 2345-2355
30. Wegiel B, Bjartell A, Culig Z, Persson JL,. Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer 2008; 122: 1521-1529
31. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC,. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003; 9: 370-376
32. Kroon P, Berry PA, Stower MJ, et=al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res 2013; 73: 5288-5298
33. Steiner H, Berger AP, Godoy-Tundidor S, et=al. An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6. Eur J Cancer 2004; 40: 1066-1072
34. Pallares J, Rojo F, Iriarte J, Morote J, Armadans LI, de Torres I,. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol 2006; 21: 857-865
35. Shariat SF, Chromecki TF, Hoefer J, et=al. Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. J Urol 2011; 186: 2107-2114
36. Deeble PD, Murphy DJ, Parsons SJ, Cox ME,. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 2001; 21: 8471-8482
37. Shukla S, MacLennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S,. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 2007; 121: 1424-1432
38. Santer FR, Malinowska K, Culig Z, Cavarretta IT,. Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Rel Cancer 2010; 17: 241-253
39. Kalluri R, Weinberg RA,. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428
40. Shiota M, Bishop JL, Nip KM, et=al. Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res 2013; 73: 3109-3119
41. Giannoni E, Bianchini F, Masieri L, et=al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res 2010; 70: 6945-6956
42. Bellido T, Borba VZ, Roberson P, Manolagas SC,. Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology 1997; 138: 3666-3676
43. Morrissey C, Lai JS, Brown LG, et=al. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate 2010; 70: 412-424
44. Taichman RS, Loberg RD, Mehra R, Pienta KJ,. The evolving biology and treatment of prostate cancer. J Clin Invest 2007; 117: 2351-2361
45. Lu Y, Zhang J, Dai J, et=al. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis 2004; 21: 399-408
46. Zhu ML, Kyprianou N,. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Rel Cancer 2008; 15: 841-849
47. Hobisch A, Eder IE, Putz T, et=al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998; 58: 4640-4645
48. Zhang J, Pugh TD, Stebler B, Ershler WB, Keller ET,. Orchiectomy increases bone marrow interleukin-6 levels in mice. Calcif Tissue Int 1998; 62: 219-226
49. Chun JY, Nadiminty N, Dutt S, et=al. Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res 2009; 15: 4815-4822
50. Domingo-Domenech J, Oliva C, Rovira A, et=al. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 2006; 12: 5578-5586
51. Steiner H, Cavarretta IT, Moser PL, et=al. Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328. Prostate 2006; 66: 1744-1752
52. Wallner L, Dai J, Escara-Wilke J, et=al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 2006; 66: 3087-3095
53. Dorff TB, Goldman B, Pinski JK, et=al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 2010; 16: 3028-3034
54. Fizazi K, De Bono JS, Flechon A, et=al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer 2012; 48: 85-93
55. Karkera J, Steiner H, Li W, et=al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesisin prostate cancer patients from a phase 1 study. Prostate 2011; 71: 1455-1465